Cytokinetics Wins EU Approval for Cardiovascular Drug Myqorzo

Key Takeaways Cytokinetics won EC approval for Myqorzo to treat adults with symptomatic obstructive HCM.Myqorzo showed significant pVO2 improvement in the phase III SEQUOIA-HCM study at 24 weeks.CYTK now has approvals in the U.S., EU and China, targeting a sizable oHCM market opportunity.Cytokinetics, Incorporated (CYTK) announced that the European Commission (EC) has approved Myqorzo (aficamten), 5 mg, 10 mg, 15 mg and 20 mg tablets, for the treatment of adult patients with symptomatic obstructive hypertro ...